Skip to content

Mersana Therapeutics, Inc.

CIK 0001442836

← back to feed
Revenue (TTM)
$29.42M
+9.9% YoY Q3 Nov 2025
Net Income (TTM)
−$67.47M
+59.7% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$8.91
+62.2% YoY Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
—
Q3 Nov 2025
Net Margin
-229.3%
Q3 Nov 2025
Free Cash Flow (TTM)
−$100.32M
Q3 Nov 2025
Cash
$56.39M
Q3 Nov 2025
Total Debt
$2.08M
Q3 Nov 2025
Shares Outstanding
5M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings